AstraZeneca’s Challenge to Price Negotiation Fails in Federal District Court
FDA Law Blog
MARCH 5, 2024
In granting the Government’s summary judgment motion, the court held that AstraZeneca did not have the requisite standing for the APA arguments because it failed to identify a cognizable injury-in-fact that could be redressed by vacatur of the Guidance. Opinion at 17. see also 42 U.S.C. 1320f-1(e)(1)(A).
64 
Let's personalize your content